MASH Clinical Trials

Nov 09 2025
Convention Center: Hall A (General Session), Concourse Level
2:00 PM - 3:30 PM

World Class Speakers

Quentin M Anstee, MBBS, PhD, FRCP
Abstract Presenter

Quentin M Anstee, MBBS, PhD, FRCP

Newcastle University, UK
Naim Alkhouri, MD, FAASLD
Abstract Presenter

Naim Alkhouri, MD, FAASLD

Summit Clinical Research
Mazen Noureddin
Abstract Presenter

Mazen Noureddin

Houston Research Institute and Houston Methodist Hospital
Niharika Samala, MBBS
Abstract Presenter

Niharika Samala, MBBS

Indiana University
Mary E. Rinella, MD, FAASLD
Moderator

Mary E. Rinella, MD, FAASLD

The University of Chicago
Jörn M Schattenberg, MD
Moderator

Jörn M Schattenberg, MD

Saarland University Medical Center Homburg

Description

Researchers in this abstract parallel session will share the results of recent clinical trials in MASH.

Journey Maps

Presentations

2:00 PM - 2:15 PM
Apr 29 2026
Washington, D.C.

Improvements in non-invasive biomarkers and biopsy responses with the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: concordance analysis from a phase 2 trial in people with metabolic dysfunction–associated steatohepatitis and fibrosis

Quentin M Anstee, MBBS, PhD, FRCP , Abstract Presenter
MASLD
2:15 PM - 2:30 PM
Apr 29 2026
Washington, D.C.

A randomized, placebo-controlled, phase 2 study of the safety and efficacy of combination treatment with semaglutide, cilofexor and firsocostat in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (WAYFIND)

Naim Alkhouri, MD, FAASLD , Abstract Presenter
MASLD
2:45 PM - 3:00 PM
Apr 29 2026
Washington, D.C.

Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trial (SYMMETRY)

Mazen Noureddin , Abstract Presenter
MASLD
3:00 PM - 3:15 PM
Apr 29 2026
Washington, D.C.

Saroglitazar improves hepatic steatosis in women with PCOS and MASLD: Results of EVIDENCES VII randomized control study

Niharika Samala, MBBS , Abstract Presenter
MASLD

Objectives

  • Describe new efficacy and safety data from recent MASH clinical trials, highlighting potential therapeutic advances.
  • Analyze key secondary outcomes and subgroup findings to identify implications for patient selection and the effect on clinical trials.